Project Grant R21CA318045
Award Date 8/26/26
Completion Date 7/31/28
Dollars Obligated $429K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78712, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded The University of Texas Southwestern Medical Center $688,012 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel RPS23 inhibitors for the treatment of acute myeloid leukemia. The funded research develops ligands that bind the ribosomal protein RPS23 and activate the integrated stress response through the GCN2 kinase pathway, triggering apoptosis in leukemia cells. The investigator-led...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $421,685 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize clonal evolution and immune dysregulation in acute myeloid leukemia patients treated with venetoclax and azacitidine following allogeneic stem cell transplantation. The research addresses post-transplant AML relapse mechanisms by pursuing two primary aims: characterizing the mutational landscape at diagnosis,...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $639,514 on June 1, 2026, for mechanistic characterization of NVL inhibition by benzothiazepinones as a non-genotoxic chemotherapy strategy under the Cancer Biology Research program (CFDA 93.396). The award funds research to define the catalytic mechanism of NVL, an essential AAA+ ATPase required for large ribosomal subunit...
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,881 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors of ASH1L, a histone methyltransferase, as a therapeutic strategy for acute leukemia. The funded research targets acute myeloid leukemia (AML), which carries a five-year survival rate of approximately 27% with current treatments. The work focuses on blocking expression of HOX genes—particularly...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas at Austin $396,377 on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The project integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute awarded Albert Einstein College of Medicine $885,632 under the Cancer Treatment Research program (CFDA 93.395) on April 2, 2026, to interrogate erythroid differentiation and the BCL-XL axis in TP53-mutated acute myeloid leukemia. The research addresses TP53-mutated AML, which accounts for approximately 15–20 percent of AML patients and carries poor prognosis (median survival less than six months) and resistance to conventional therapies including the BCL-2 inhibitor...